Evidence map›Paper›PMID 33201172›Full record

ArticleBioscience reports2020

Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study.

Gianluca E M Boari, Giulia Chiarini, Silvia Bonetti, Paolo Malerba, Gianluca Bianco, Cristina Faustini, Federico Braglia-Orlandini, Daniele Turini, Vittoria Guarinoni, Michele Saottini and 10 more

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Gianluca E M BoariDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Giulia ChiariniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Silvia BonettiDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Paolo MalerbaDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Gianluca BiancoDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Cristina FaustiniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Federico Braglia-OrlandiniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Daniele TuriniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Vittoria GuarinoniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Michele SaottiniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Sara ViolaDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Giulia Ferrari-ToninelliDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Giancarlo PasiniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Cristina MascadriDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Bianca BonziDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Paolo DesenzaniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Claudia TusiDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Eros ZanottiDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Matteo NardinDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Damiano RizzoniDivision of Medicine, Covid-19 Unit M, Spedali Civili di Brescia, Montichiari, Brescia, Italy.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to simultaneously assess several potential predictors of outcome (co-morbidity, previous and in-hospital treatment, radiologic Brixia score) in patients with COVID-19. This retrospective cohort study included 258 consecutive patients with confirmed COVID-19 admitted to a medical ward at Montichiari Hospital, Brescia, Italy from February 28th to April 30rd, 2020. Patients had SARS-CoV-2 related pneumonia with respiratory failure, and were treated with hydroxychloroquine and lopinavir plus ritonavir. In some patients, additional treatment with tocilizumab, dexamethasone and enoxaparin was adopted. Outcomes (death or recovery) were assessed at the end of the discharge period or at the end of the follow-up (August 2020). During hospitalization, 59 patients died, while 6 died after discharge. The following variables were demonstrated to be associated with a worse prognosis: Radiologic Brixia score higher than 8, presence at baseline of hypertension, diabetes, chronic obstructive pulmonary disease, heart disease, cancer, previous treatment with ACE-inhibitors or anti-platelet drugs. Anticoagulant treatment during hospital admission with enoxaparin at a dose higher than 4000 U once daily was associated with a better prognosis. In conclusion, our study demonstrates that some co-morbidities and cardiovascular risk factors may affect prognosis. The radiologic Brixia score may be a useful tool to stratify the risk of death at baseline. Anticoagulant treatment with enoxaparin might be associated to a clinical benefit in terms of survival in patients with COVID-19.

Indexed as

COVID-19 Drug TreatmentAgedAged, 80 and overAnticoagulantsAntiviral AgentsCardiovascular DiseasesComorbidityCOVID-19EnoxaparinFemaleHumansHydroxychloroquineItalyLopinavirMalePrognosisAnticoagulantsAntiviral AgentsEnoxaparinHydroxychloroquineLopinavirRitonavirACE-inhibitorscardiovascular risk factorsCOVID-19enoxaparinhypertensionSARS-CoV2

Identifiers

PMID33201172
PMCPMC7724688
OpenAlexW3103926835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.